Blocking effect of NIP-142 on the KCNQ1/KCNE1 channel current expressed in HEK293 cells

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 1, 2011, Pages 153-155

  Namekata, Iyuki ^a   Tsuruoka, Noriko ^a   Tsuneoka, Yayoi ^a   Matsuda, Tomoyuki ^a,b   Takahara, Akira ^a   Tanaka, Yoshio ^a   Suzuki, Takeshi ^a,c   Takahashi, Tetsuo ^a   Iida Tanaka, Naoko ^a,d   Tanaka, Hikaru ^a  

^a TOHO UNIVERSITY   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

^c JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^d OTSUMA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; KCNE1; KCNQ1; NIP 142

Indexed keywords

4 CYCLOPROPYLAMINO 3,4 DIHYDRO 2,2 DIMETHYL 6 (4 METHOXYPHENYLACETYLAMINO) 7 NITRO 2H 1 BENZOPYRAN 3 OL; CHROMANOL 293B; NIP 142; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POTASSIUM CURRENT; PROTEIN EXPRESSION;

ANTI-ARRHYTHMIA AGENTS; BENZOPYRANS; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; KCNQ1 POTASSIUM CHANNEL; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 78951475030     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.153     Document Type: Article

References (17)

1. Sugimoto T., Hayakawa K., Kasanuki H., "Atrial Fibrillation, Flutter, and Tachycardia" ed. by Hayakawa K., Kasanuki H., Igaku-Shoin, Tokyo, 1999, pp. 14-18.
2. Aliot E., Denjoy I., Am. J. Cardiol., 77, 66A-71A (1996).
3. Iwasaki H., Takahara A., Nakamura Y., Satoh Y., Nagai T., Shinkai N., Sugiyama A., J. Pharmacol. Sci., 110, 410-414 (2009).
4. Lenz T., Hilleman D., Drugs Today (Barc), 36, 759-771 (2000).
5. Nagasawa H., Fujiki A., Fujikura N., Matsuda T., Yamashita T., Inoue H., Circ. J., 66, 185-191 (2002).
6. Tanaka H., Hashimoto N., Cardiovas. Drug Rev., 25, 342-356 (2007).
7. Hashimoto N., Tanaka H., "Progress in Cardiac Arrhythmia Research," ed. by Tarkowicz I. R., Nova Science Publishers, Hauppague, 2009, pp. 125-139.
8. Matsuda T., Takeda K., Ito M., Yamagishi R., Tamura M., Nakamura H., Tsuruoka N., Saito T., Masumiya H., Suzuki T., Iida-Tanaka N., Itokawa M., Yamashita T., Tsuruzoe N., Tanaka H., Shigenobu K., J. Pharmacol. Sci., 98, 33-40 (2005).
9. Matsuda T., Ito M., Ishimaru S., Tsuruoka N., Saito T., Iida-Tanaka N., Hashimoto N., Yamashita T., Tsuruzoe N., Tanaka H., Shigenobu K., J. Pharmacol. Sci., 101, 303-310 (2006).
10. Matsuda T., Masumiya H., Tanaka N., Yamashita T., Tsuruzoe N., Tanaka Y., Tanaka H., Shigenobu K., Life Sci., 68, 2017-2024 (2001).
11. Bosch R. F., Gaspo R., Busch A. E., Lang H. J., Li G. R., Nattel S., Cardiovas. Res., 38, 441-450 (1998).
12. Sanguinetti M. C., Jurkiewicz N. K., Scott A., Siegl K. S., Circ. Res., 68, 77-84 (1991).
13. Zankov D. P., Omatsu-Kanbe M., Isono T., Toyoda F., Ding W. G., Matsuura H., Horie M., Circulation, 113, 1278-1286 (2006).
14. Chen Y. H., Xu S. J., Bendahhou S., Wang Y., Xu W. Y., Jin H. W., Sun H., Su X. Y., Zhuang Q. N., Yang Y. Q., Li Y. B., Liu Y., Xu H. J., Li X. F., Ma N., Mou C. P., Chen Z., Barhanin J., Huang W., Science, 299, 251-254 (2003).
15. Salataa J. J., Seinickb H. G., Lynch J. J. Jr., Curr. Med. Chem., 11, 29-44 (2004).
16. Tanaka H., Namekata I., Ogawa T., Tsuneoka Y., Komikado C., Takahara A., Iida-Tanaka N., Izumi-Nakaseko H., Tsuru H., Adachi-Akahane S., Eur. J. Pharmacol., 649, 263-267 (2010).
17. Matsuda T., Masumiya H., Saito T., Tanaka H., Shigenobu K., Jpn. J. Pharmacol., 79 (Suppl. I), 178P (1999).